6e10 against aβ1 16

The following antibodies were utilised in our study: 6E10 (against Aβ1–16) from Covance; MOAB-2 clone 6C3 against Aβ from Merck-Millipore (Burlington, MA, USA); anti-apolipoprotein E (ApoE) and Aquaporin-4 (AQP-4) from Santa Cruz; anti-insulin-degrading enzyme (IDE) and anti-β-actin from Abcam; anti-ionized calcium-binding adaptor molecule 1 (Iba1) from Wako; anti-CD68 from Biolegend; Rat anti-GFAP (clone 2.2B10) from Invitrogen or from DAKO; anti-fibrinogen from DAKO and anti-CD31 from BD Biosciences. All other reagents were purchased from Invitrogen or Sigma, unless otherwise indicated.

The antibodies used for detection of proteins of interest were 6E10 (against Aβ1-16) from Covance, R1(57) against the carboxy terminus of APP was a kind gift from Dr P. Mehta (NYS Institute for Basic Research in Developmental Disabilities); anti-BACE1 was from Cell Signaling; anti-apolipoprotein E (ApoE) and anti-neprilysin CD10 from Santa Cruz; anti-ionized calcium-binding adapter molecule 1 (IBA1) from Wako; anti-glial fibrillary acidic protein (GFAP) (clone 2.2B10), anti-Aβ (6C3), and anti-neuronal nuclei (NeuN) were from Millipore; and anti-insulin degrading enzyme (IDE), Aldehyde dehydrogenase 1A (Aldh1a1), and anti-β-actin were from Abcam. Tissue culture reagents were purchased from Invitrogen and Millipore, and all other reagents were purchased from Sigma, unless stated otherwise.

Antibodies used included 6E10 against Aβ1-16 (Covance), 4G8 against Aβ17-24 (Covance), anti-BACE1 antibody (Cell Signalling), anti-neprilysin antibody (Santa Cruz), anti-insulin degrading enzyme (IDE) antibody (Abcam), anti-ANXA1 antibody (Zymed), anti-β-actin antibody (Abcam), anti-IgG antibody (Abcam), anti-FPRL1/FPR2 antibody (Acris Antibodies GmbH) and anti-IgG FITC conjugated antibody (AbD Serotec). Full-length human recombinant (hr) ANXA1 was obtained as previously described [16 (link)], and protein was purified by GTP Technology (Labege Cedex). Synthetic Aβ_1–42, 5-FAM-labelled Aβ_1–42 and Aβ_1–42 scrambled peptides were obtained from Anaspec. Synthetic Aβ_1–42 was prepared by suspension of the lyophilised Aβ_1–42 in DMSO to 500 μM and then diluted to different concentrations ranging from 0.1 to 3 μM with cold DMEM. FPR2 inhibitors WRW4 and Boc-1 were obtained from Tocris Bioscience. Tissue culture reagents were obtained from Invitrogen. All other chemicals and reagents were purchased from Sigma-Aldrich, Qiagen and Invitrogen.